| Project Number | pCODR 10119 |
|---|---|
| Brand Name | Stivarga |
| Generic Name | Regorafenib |
| Strength | 40 mg |
| Tumour Type | Gastrointestinal |
| Indication | Unresectable Hepatocellular Carcinoma (HCC) |
| Funding Request | For treatment of patients with unresectable hepatocellular carcinoma (HCC) who have been previously treated with sorafenib |
| Review Status | Open for Input on Submission |
| Pre Noc Submission | No |
| NOC Date | September 18, 2017 |
| Manufacturer | Bayer Inc. |
| Submitter | Bayer Inc. |
| Submission Date | October 12, 2017 |
| Submission Type | New Indication |
| Prioritization Requested | Requested |
| Stakeholder Input Deadline ‡ | October 26, 2017 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.